

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 40%;">Application Number</td> <td>09/709,170</td> </tr> <tr> <td>Filing Date</td> <td>November 10, 2000</td> </tr> <tr> <td>First Named Inventor</td> <td>Warrell, Raymond</td> </tr> <tr> <td>Art Unit</td> <td>1635</td> </tr> <tr> <td>Examiner Name</td> <td>Gibbs, Terra C.</td> </tr> </table>		Application Number	09/709,170	Filing Date	November 10, 2000	First Named Inventor	Warrell, Raymond	Art Unit	1635	Examiner Name	Gibbs, Terra C.
Application Number	09/709,170														
Filing Date	November 10, 2000														
First Named Inventor	Warrell, Raymond														
Art Unit	1635														
Examiner Name	Gibbs, Terra C.														
Sheet	1	of	2	Attorney Docket No: GEN0008-01US											

US PATENT DOCUMENTS					
Examiner Initial *	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of cited Document	T ²

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
		"USPTO Final Office Action mailed 10/14/08 for U.S. Application Serial No. 10/738,867 filed 12/16/03", 23 pp.		
		"International Search Report for PCT/US03/41433", (01/11/2005), 3 pp.		
		CHESON, "Hematologic Malignancies: New Development and Future Treatments", <u>Seminars in Oncology</u> Vol. 29, No. 4 (supplement 13), (2002 Aug 29), 33-45		
		KOSMIDIS, et al., "Cisplatin/Etoposide Versus Carboplatin/Etoposide Chemotherapy and Irradiation in Small Cell Lung Cancer: A Randomized Phase III Study", <u>Seminars in Oncology</u> , Vol 2, No. 3 (supplement 6), (1994 Jun.), 23-30		
		LOPES, et al., "Molecular and Pharmacokinetic Properties Associated with the Therapeutics of Bcl-2 Antisense Oligonucleotide G3139 Combined with Free and Liposomal Doxorubicin", <u>Clinical Cancer Research</u> , Vol. 6, (2000 Jul.), 2891-2902		
		MIAYAKE, et al., "Chemosensitization and Delayed Androgen-Independent Recurrence of Prostate Cancer with the Use of Antisense Bcl-2 Oligodeoxynucleotides", <u>Journal of the National Cancer Institute</u> , Vol. 92, No. 1, (2005 Jan. 5), 34-41		
		TOLCHER, "Preliminary Phase I Results of G3139 (bcl-2 Antisense Oligonucleotide) Therapy in Combination with Docetaxel in Hormone-Refractory Prostate Cancer", <u>Seminars in Oncology</u> , Vol. 28, No. 4 (supplement 15), (2001 Aug.), 67-70		
		JANSEN, B. et al., "Chemosensitisation of malignant melanoma by BCL-2 antisense therapy", <u>Early Report: The Lancet</u> , Volume 356, (Nov. 18, 2000), 1728-1733		
		MCLAUGHLIN, P. et al., "Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program", <u>J. of Clinical Oncology</u> , Vol. 16:8, (August 1998), 2825-2833		

EXAMINER

DATE CONSIDERED

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 40%;">Application Number</td> <td>09/709,170</td> </tr> <tr> <td>Filing Date</td> <td>November 10, 2000</td> </tr> <tr> <td>First Named Inventor</td> <td>Warrell, Raymond</td> </tr> <tr> <td>Art Unit</td> <td>1635</td> </tr> <tr> <td>Examiner Name</td> <td>Gibbs, Terra C.</td> </tr> </table>		Application Number	09/709,170	Filing Date	November 10, 2000	First Named Inventor	Warrell, Raymond	Art Unit	1635	Examiner Name	Gibbs, Terra C.
Application Number	09/709,170														
Filing Date	November 10, 2000														
First Named Inventor	Warrell, Raymond														
Art Unit	1635														
Examiner Name	Gibbs, Terra C.														
Sheet	2	of	2	Attorney Docket No: GEN0008-01US											

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		CHI, KIM et al., "A Phase I Trial of an Antisense Oligonucleotide to BCL-2 (G3139, Genta) and Mitoxantrone in Patients with Metastatic Hormone Refractory Prostate Cancer (HRPC)", <u>Meeting: 2000 ASCO Annual Meeting, Abs. No.: 1299, 1 pp.</u>	
		CHI, KIM et al., "A Phase I Dose-finding Study of Combined Treatment with an Antisense Bcl-2 Oligonucleotide(Genasense) and Mitoxantrone in Patients with Metastatic Hormone-refractory Prostate Cancer", <u>Clinical Cancer Research, vol. 7, (December 2001), 3920-3927</u>	
		BANERJEE, DEBABRATA <u>Genasense Genta Inc. Current Opinion In Investigational Drugs 2001 2(4), (2001), 574-580</u>	
		CHEN, HELEN et al., "A Phase I Study of BCL-2 Antisense G3139 (GENTA) and Weekly Docetaxel in Patients with Advanced Breast Cancer and Other Solid Tumors", <u>Meeting: 2000 ASCO Annual Meeting, Abs. No.: 692, 1 pp.</u>	
		SCHER, HOWARD et al., "A Phase I Trial of G3139 (Genta. Inc.), a BCL-2 Antisense Drug by Continuous Infusion (CI) as a Single Agent and with Weekly Taxol (T)", <u>Meeting: 2000 ASCO Annual Meeting, Abs. No.: 774, 1</u>	
		"International Preliminary Examination Report for PCT/US03/41433 (Sep. 13, 2005) 5 pp.",	
		IYER, et al., ""Clinical pharmacology of camptothecins"", <u>Cancer Chemother Pharmacol, (1998),42 (Suppl): S31-S-43</u>	

EXAMINER

DATE CONSIDERED